Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
IMCR
Home
/
IMCR

NASDAQ
$29.23
$29.23

Overview

Price performance
Low
$28.80
High
$30.99
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
29.23
-0.80 (-2.66%)
Average, 50 days
$32.09
$31.73
Open
$30.65
Previous close
$30.03
52-week high
$40.71
Dec 5, 2025 (1 year ago)
52-week low
$27.50
Oct 14, 2026 (22 days ago)
6.29%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
1.51B
Volume
685 796
Total Return (3M)
-12.06%
Total Return (1Y)
-8.40%
5.87
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
GB
Website
immunocore.com
About
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

Frequently asked questions

IMCR · Immunocore Holdings plc

01What is Immunocore Holdings plc stock price today?

The current price of IMCR is $29.23 — it has decreased by 2.66% since the previous close. Data as of Nov 4, 2026.

02Is Immunocore Holdings plc stock price growing?

IMCR is down 5.71% over the past week, down 1.62% over the past month and down 8.40% over the past year. The price is below its 200-day moving average of $31.73.

03What is IMCR stock forecast?

Analysts' average 12-month price target for IMCR is $39.00, which implies 33.42% upside from the current price. Individual estimates range from $35.00 to $43.00.

04What do analysts say about IMCR stock?

Of the 13 analysts covering Immunocore Holdings plc, 2 rate it a strong buy, 7 rate it a buy and 4 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is Immunocore Holdings plc market cap?

Immunocore Holdings plc has a market capitalization of $1.51B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Immunocore Holdings plc earnings last quarter?

In its most recent quarterly report, Immunocore Holdings plc posted a loss of $0.02 per share against an estimate of -$0.01, missing expectations by 100.00%. Upcoming reports are listed in the earnings calendar.

07What is Immunocore Holdings plc revenue for the last quarter?

Immunocore Holdings plc reported revenue of $115.93M in its most recent quarter, which has decreased by 13.71% compared with the same quarter a year earlier. Analysts had expected $148.84M.

08Does Immunocore Holdings plc pay dividends?

Immunocore Holdings plc has not paid any dividends over the past year.

09Who are Immunocore Holdings plc competitors?

Companies most comparable to Immunocore Holdings plc include BioNTech SE, ImmunityBio, Inc., Xencor, Inc., Arcus Biosciences, Inc. and Janux Therapeutics, Inc.

10How volatile is IMCR stock?

In the latest trading session IMCR moved between $28.80 and $30.99, a range of 7.49% of its current price.

11Should I invest in Immunocore Holdings plc stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Immunocore Holdings plc shows a strong sell rating today and a strong sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Immunocore Holdings plc is sell. Technical ratings are indicators, not investment advice.

12What are IMCR stock 52-week high and low?

Over the past 52 weeks IMCR has traded between $27.50 and $40.71. The current price is 28.20% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.